

**Sanofi and COVID-19 (coronavirus)**

**Information about the supply and distribution of Sanofi Medicines in the UK**

As Sanofi UK continues to closely monitor the coronavirus situation, our immediate priorities are the continued supply of our medicines and the health and safety of our staff, healthcare partners and communities.

In this document you’ll receive answers to the following questions:

* Is there a risk of shortage because of the outbreak?
* Will there be an impact on you and your patients?
* What is the impact on Insulin supply and manufacture?
* What to do if you have any issues with supply of any Sanofi Medicine?

On behalf of Sanofi, thank you for the work you are doing for patients and the wider population at this difficult time.

**Is there a risk of shortage because of the outbreak?**

The situation is evolving very quickly as many local governments and authorities are currently taking critical decisions to fight against the Covid-19 outbreak. In that context, **Sanofi’s priority is to do whatever is possible to ensure continuous access to medicines that are essential to patients’ needs**.

Sanofi is monitoring the situation very closely and putting specific actions in place to enable business continuity, and the supply and distribution of our important medicines. As of today, our global industrial network is operational (including France, China and Italy), and **the diversity of our sourcing allows for the time being business continuity across all our product lines**.

**Will there be an impact on you and your patients?**

It is too soon to predict and assess the impact the outbreak might have. **Our focus is ensuring we are adhering to government advice to help control the epidemic, to do whatever we can to ensure medicines will continue to get to patients and enable supply continuity and to ensure the safety of our employees**.

In addition, Sanofi Supply Chain are meeting, remotely, every week with the Department of Health and Social Care (DHSC) and the Commissioned Medicines Unit (CMU) to ensure all information about any future challenges or anticipated peaks in demand have plans in place.

**What about the continuity of insulin manufacturing and supply in the case of massive contagion and potential manufacturing lockdown?**

Our industrial affairs (IA) operations do their utmost to ensure that insulins continue to be available to the people who need them. To ensure that the required employees can be present, specific health and safety measures have been implemented in our industrial sites. Sufficient supply of primary and secondary packaging materials has also been secured.

Our insulins supply chain is fully functional, and has adapted to changes in distribution systems (longer border-crossing times, fewer cargo planes, etc.) . At this time, we do not anticipate disruption to our insulin production or distribution operations resulting from the current COVID-19 pandemic.

Sanofi is closely monitoring our internal situation and putting specific actions in place to enable business continuity and the supply and distribution of our important medicines.

**What to do if you have any issues obtaining any Sanofi Medicine?**

If you have any questions or concerns, please know that our business continuity plan has kicked in, so we’re here to support you.

**Supply services** Our dedicated Customer Services team are continuing to support Health Care Professionals and their patients by closely managing supply down to individual pharmacy level. To contact them directly please call 0800 854 430, fax 0800 471 5125 or email GB-CustomerServices@sanofi.com

**Medical questions** For any specific medical questions regarding any Sanofi medicines, please contact Sanofi UK Medical Information on 0845 372 7101 or uk-medicalinformation@sanofi.com